Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer

摘要: Abstract Objective . The purpose of this study was to determine the feasibility, response rate, and toxicity paclitaxel, carboplatin, gemcitabine as an outpatient regimen in treatment ovarian/non-ovarian tubal adenocarcinoma. This is largest completed using first-line these patients. Methods Following cytoreductive surgery, eligible patients were initially treated with paclitaxel (175 mg/m 2 via 1 h infusion), carboplatin (AUC = 5), (800 ) every 21 days. Gemcitabine repeated on day 8. After six cycles treatment, responders for additional three gemcitabine. Colony-stimulating factors used at discretion treating physician. Results Fifty-seven (median age=58; range 41–81) stage III/IV epithelial carcinoma ovary, fallopian tube, peritoneum received a total 476 chemotherapy. Grades 3 4 neutropenia developed 19.7% 9% while grades thrombocytopenia 4.2% 1.3% cycles. One hundred thirty-seven (28.8%) possible delayed primarily due neutropenia. Forty-five (84.9%) exhibited complete (5.7%) demonstrated partial response, rate 90.4%. Twenty-two some degree neuropathy, although there no reported interference activities daily living. patients' median progression-free interval overall survival 15.5 40.8 months, respectively. Forty-one original 57 alive conclusion data collection. Conclusions report represents world employing triplet advanced ovarian, or peritoneal cancer Although high neuropathy encountered study, need eliminate 54% bone marrow suppression merits further investigation dosing schedule. More recent suggest that lower doses 2-week may be effective less toxicity. A comparison our results GOG-0182 utilizes same regimen, should informative.